Table 2:
Baseline absolute metabolite concentrations in NAWM, LWM, and GMa
| Natalizumab (n = 25) |
IFNb/GA (n = 18) |
Controls (n = 12) |
||||||
|---|---|---|---|---|---|---|---|---|
| NAWM | LWM | GM | NAWM | LWM | GM | WM | GM | |
| tCr | ||||||||
| Frontal | 4.86 ± 0.71 | 4.35c ± 0.58 | 8.70 ± 1.89 | 4.93 ± 0.92 | 4.95 ± 0.90 | 8.70 ± 1.41 | 4.93 ± 0.64 | 8.48 ± 1.31 |
| Semiovale | 4.67 ± 0.63 | 4.30c ± 0.81 | 4.83 ± 0.75 | 4.41b ± 0.77 | 4.72 ± 0.60 | |||
| Parietal | 4.52 ± 0.62 | 4.42 ± 0.52 | 7.78 ± 0.88 | 4.72 ± 0.69 | 4.57 ± 0.93 | 8.24 ± 1.02 | 4.58 ± 0.45 | 7.48 ± 0.99 |
| tNAA | ||||||||
| Frontal | 7.17 ± 1.20 | 5.89c ± 0.81 | 11.1 ± 1.74 | 7.06 ± 1.16 | 6.75 ± 1.54 | 10.93 ± 1.61 | 7.62 ± 0.96 | 11.66 ± 1.37 |
| Semiovale | 7.96 ± 0.87 | 6.70c ± 1.51 | 8.25 ± 1.56 | 7.05c ± 1.17 | 8.51 ± 0.94 | |||
| Parietal | 7.43d ± 1.05 | 6.55c ± 0.74 | 10.51 ± 1.08 | 7.59 ± 0.98 | 7.08 ± 1.24 | 11.52 ± 1.46 | 8.22 ± 0.81 | 10.89 ± 1.30 |
| Cho | ||||||||
| Frontal | 1.50 ± 0.20 | 1.51 ± 0.25 | 2.16 ± 0.49 | 1.59 ± 0.28 | 1.64 ± 0.29 | 2.11 ± 0.45 | 1.62 ± 0.25 | 2.08 ± 0.39 |
| Semiovale | 1.44 ± 0.19 | 1.42 ± 0.28 | 1.53 ± 0.21 | 1.49 ± 0.28 | 1.49 ± 0.16 | |||
| Parietal | 1.13 ± 0.24 | 1.36 ± 0.19 | 1.31 ± 0.22 | 1.34 ± 0.23 | 1.39 ± 0.27 | 1.36 ± 0.24 | 1.37 ± 0.17 | 1.13 ± 0.20 |
| mIns | ||||||||
| Frontal | 4.82e ± 1.18 | 5.29 ± 1.01 | 7.49 ± 1.57 | 4.44 ± 0.92 | 5.45c ± 1.51 | 7.30 ± 1.11 | 3.90 ± 0.65 | 7.00 ± 1.16 |
| Semiovale | 4.47e ± 1.18 | 4.76 ± 0.91 | 4.27 ± 0.69 | 4.71 ± 1.01 | 3.56 ± 0.44 | |||
| Parietal | 4.79e ± 0.64 | 5.59b ± 1.07 | 6.47 ± 0.91 | 4.98 ± 0.93 | 5.32 ± 1.42 | 6.47 ± 0.83 | 4.01 ± 0.62 | 5.85 ± 0.52 |
| Glu | ||||||||
| Frontal | 6.34 ± 1.46 | 5.36b ± 1.13 | 12.96 ± 2.98 | 5.86 ± 1.18 | 6.03 ± 1.48 | 12.71 ± 2.57 | 6.25 ± 0.96 | 14.01 ± 2.40 |
| Semiovale | 5.38 ± 1.08 | 4.73b ± 1.16 | 5.50 ± 0.91 | 5.11 ± 0.96 | 5.49 ± 0.72 | |||
| Parietal | 5.17 ± 1.34 | 4.22b ± 0.94 | 12.99 ± 3.87 | 5.37 ± 1.57 | 4.80 ± 0.68 | 12.68 ± 1.44 | 5.31 ± 0.67 | 11.81 ± 1.85 |
In mmol/L tissue, mean ± SD. Absolute metabolite concentrations (mmol/L) of NAWM, GM, WM, and LWM in the frontal, centrum semiovale, and parietal regions averaged over the subjects at the baseline measurement.
Significant difference within the group between NAWM and LWM in the same region of the baseline measurement (P < .05).
Significant difference within the group between NAWM and LWM in the same region of the baseline (P < .01).
Significant differences between patients treated with natalizumab and healthy controls including all the time points (P < .05).
Significant differences between patients treated with natalizumab and healthy controls including all the time points (P < .01).